Vlado Perkovic

1.8k total citations · 3 hit papers
14 papers, 813 citations indexed

About

Vlado Perkovic is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Vlado Perkovic has authored 14 papers receiving a total of 813 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Nephrology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Vlado Perkovic's work include Diabetes Treatment and Management (8 papers), Renal Diseases and Glomerulopathies (3 papers) and Diabetes Management and Research (3 papers). Vlado Perkovic is often cited by papers focused on Diabetes Treatment and Management (8 papers), Renal Diseases and Glomerulopathies (3 papers) and Diabetes Management and Research (3 papers). Vlado Perkovic collaborates with scholars based in Australia, United States and Canada. Vlado Perkovic's co-authors include Kenneth W. Mahaffey, Peter Rossing, Katherine R. Tuttle, Johannes F.E. Mann, Thomas Idorn, Florian M.M. Baeres, George L. Bakris, Nanna L. Lausvig, Richard Pratley and Heidrun Bosch‐Traberg and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Kidney International.

In The Last Decade

Vlado Perkovic

9 papers receiving 793 citations

Hit Papers

Effects of Semaglutide on... 2024 2026 2024 2024 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    2024 656 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    2024 80 citations Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology profile →
  3. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
    2024 50 citations Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vlado Perkovic Australia 4 592 176 161 151 141 14 813
Richard Pratley United States 6 746 1.3× 233 1.3× 197 1.2× 187 1.2× 195 1.4× 9 997
Nanna L. Lausvig United States 7 816 1.4× 207 1.2× 335 2.1× 213 1.4× 127 0.9× 7 1.0k
Ronnie Har Canada 10 472 0.8× 220 1.3× 165 1.0× 77 0.5× 264 1.9× 13 753
Francis Chun Chung Chow Hong Kong 11 661 1.1× 187 1.1× 296 1.8× 127 0.8× 67 0.5× 16 855
Zin Zin Htike United Kingdom 10 804 1.4× 283 1.6× 365 2.3× 180 1.2× 102 0.7× 14 924
Aliza Rozenberg Israel 13 663 1.1× 266 1.5× 206 1.3× 62 0.4× 59 0.4× 26 753
Ilan Yanuv Israel 13 663 1.1× 265 1.5× 206 1.3× 62 0.4× 59 0.4× 25 751
Tomio Jinnouchi Japan 15 363 0.6× 161 0.9× 145 0.9× 53 0.4× 145 1.0× 38 591
Peter Merrill United States 9 531 0.9× 192 1.1× 224 1.4× 107 0.7× 245 1.7× 15 804
Juan José Gorgojo Martínez Spain 12 465 0.8× 166 0.9× 167 1.0× 186 1.2× 40 0.3× 30 586

Countries citing papers authored by Vlado Perkovic

Since Specialization
Citations

This map shows the geographic impact of Vlado Perkovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vlado Perkovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vlado Perkovic more than expected).

Fields of papers citing papers by Vlado Perkovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vlado Perkovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vlado Perkovic. The network helps show where Vlado Perkovic may publish in the future.

Co-authorship network of co-authors of Vlado Perkovic

This figure shows the co-authorship network connecting the top 25 collaborators of Vlado Perkovic. A scholar is included among the top collaborators of Vlado Perkovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vlado Perkovic. Vlado Perkovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Siriwardana, Amanda, Luke Buizen, Min Jun, et al.. (2025). Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. Diabetes Obesity and Metabolism. 27(4). 1972–1979. 1 indexed citations
2.
Wong, Muh Geot, Dana Kim, Sufang Shi, et al.. (2025). Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. Clinical Journal of the American Society of Nephrology. 20(11). 1564–1570.
3.
Mazhar, Faizan, Edouard L. Fu, Paul Hjemdahl, et al.. (2025). Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease. American Journal of Kidney Diseases. 86(3). 314–323.e1.
4.
Perkovic, Vlado, Jonathan Barratt, Richard Lafayette, et al.. (2025). Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial. Kidney International Reports. 10(12). 4207–4218.
5.
Tangri, Navdeep, et al.. (2025). From progression to remission: a new paradigm for success in chronic kidney disease. Kidney International. 109(1). 17–21.
6.
Lafayette, Richard, Hernán Trimarchi, Jonathan Barratt, et al.. (2025). WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY. Kidney International Reports. 10(2). S158–S159. 2 indexed citations
7.
Ketema, Daniel Bekele, Workagegnehu Hailu, Sunil V. Badve, et al.. (2025). Quality of care for people with chronic kidney disease: a systematic review and meta-analysis. BMJ Open. 15(9). e102044–e102044.
8.
Pratley, Richard E., Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology. 84(17). 1615–1628. 50 indexed citations breakdown →
9.
Perkovic, Vlado, Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2). 109–121. 656 indexed citations breakdown →
10.
Vaduganathan, Muthiah, Christopher P. Cannon, Meg Jardine, et al.. (2024). Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial. European Journal of Heart Failure. 26(9). 1967–1975. 1 indexed citations
11.
Badve, Sunil V., Matthew M.Y. Lee, Naveed Sattar, et al.. (2024). Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 13(1). 15–28. 80 indexed citations breakdown →
12.
Mahaffey, Kenneth W., Katherine R. Tuttle, Florian M.M. Baeres, et al.. (2024). Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. European Heart Journal. 46(12). 1096–1108. 20 indexed citations
13.
Kang, Amy, Brendan Smyth, Carol A. Pollock, et al.. (2024). Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes Obesity and Metabolism. 26(9). 3530–3540. 2 indexed citations
14.
Heerspink, Hiddo J.L., Niels Jongs, Sunil V. Badve, et al.. (2024). Canagliflozin and iron metabolism in the CREDENCE trial. Nephrology Dialysis Transplantation. 40(4). 696–706. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Pratley Breakdown of academic impact, for papers by Nanna L. Lausvig Breakdown of academic impact, for papers by Ronnie Har Breakdown of academic impact, for papers by Francis Chun Chung Chow Breakdown of academic impact, for papers by Zin Zin Htike Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Ilan Yanuv Breakdown of academic impact, for papers by Tomio Jinnouchi Breakdown of academic impact, for papers by Peter Merrill Breakdown of academic impact, for papers by Juan José Gorgojo Martínez
Rankless by CCL
2026